HELP
Fiscal year ends March Quarters are offset from the calendar — Q1 is Apr–Jun

Helus Pharma Inc. is a biotechnology company that develops treatments designed to improve mental health. The company focuses on the strategic innovation of novel serotonergic agonists (NSAs) through patient-centered research and clinical development.

Summarised from the company's own disclosures

Industry Biotechnology Homepage ir.helus.com
Sector Healthcare IR page ir.helus.com
Tags
mental health, serotonergic agonists, neuropsychiatry, drug development
Press page —

Metrics

Valuation  
Market cap $ 634.555M
Market cap (USD) $ 634.555M
P/E -2.89
PEG —
P/BV 2.74
P/S 124.42
P/OCF -4.76
P/FCF -13.06
Dividend yield —
Turnover / mcap —
Returns  
ROE -63.1%
ROI -63.9%
ROIC -63.9%
Profit margin -2,901.9%
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 16
Quality score -66.7%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 USD FY 2025 CAD FY 2024 CAD FY 2023 CAD
Revenue 5.1M — — —
Net profit -147.998M -113.137M -78.08M -47.49M
Free cash flow — — -68.929M -47.573M

Figure FY 2026 USD FY 2025 CAD FY 2024 CAD FY 2023 CAD
Share price 4.8 8.86 0.56 0.52
Price performance 12m -0.24 14.33 0.07 -0.53

Filed figures

Figure Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash flow detail
Interest paid (cash effect) (USD) — — — 0.00 -5.5M
Income detail
Research and development expense (CAD) 17.6M 25.5M 32.4M 54.9M 86.6M
Reported Jun 27, 2023 Jun 27, 2023 Jun 26, 2024 Jun 29, 2026 Jun 29, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

HLP003 achieved statistically significant and clinically meaningful results in the primary and key secondary endpoints starting as early as Day 2 and maintained at all time points

-7.6 point placebo-adjusted change from baseline at Week 6 for the primary endpoint on the Montgomery-Asberg Depression Rating Scale (“MADRS”) (p< 0.0001)

Durable effect maintained through Week 12 (key secondary endpoint) with a -7.0 point placebo-adjusted change from baseline on the MADRS (p< 0.0001)

Robust and statistically significant response and remission rates starting as early as Day 2 and maintained at all time points

HLP003 was generally well-tolerated

This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

Company to host webcast at 8:00 AM ET today

NEW YORK and TORONTO, Nov. 16, 2026 — Helus Pharma Inc.

Helus Pharma to Present Topline Results from Phase 3 APPROACH Bull 0 Bear 0 Clinical/regulatory

Study Evaluating HLP003 as Adjunctive Treatment in Major

Depressive Disorder on November 16, 2026

Company to host webcast at 8:00 a.m. EDT on Monday, November 16, 2026

NEW YORK & TORONTO - November 15, 2026 - Helus Pharma Inc. (Nasdaq: HELP) (Cboe CA: HELP) (the "Company" or "Helus Pharma"), a clinical-stage pharmaceutical company committed to improving the treatment landscape in mental health through the development and commercialization of novel serotonergic agonists ("NSAs"), today announced that it will host a webcast tomorrow at 8:00 a.m. EDT to present topline results from its Phase 3 APPROACH study evaluating HLP003 in major depressive disorder ("MDD").

Please click here to access the webcast or visit the Events & Presentations page of Helus Pharma's website. The archived webcast will be available on the Company's website on the Events & Presentations page following the presentation.

About Helus Pharma

Helus Pharma is a clinical stage pharmaceutical company committed to improving the treatment landscape in mental health through the development of NSAs, synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity.

Appointed Michael Halstead as Chief Executive Officer to lead Helus Pharma through late-stage development and commercialization

Completed enrollment in the Phase 3 APPROACH pivotal study of HLP003 in major depressive disorder (“MDD”); topline data remains on track for Q4 20261,2

Announced design of upcoming HLP004 Phase 2 monotherapy study in generalized anxiety disorder (“GAD”); expected to initiate in Q1 20271,2

Appointed Dr. Suresh Durgam, former Executive Vice President and Chief Medical Officer of Intra-Cellular Therapies, Inc. to the Company’s Board of Directors

Appointed Helus Pharma board member, Mark Lawson, independent Chair of the Board of Directors

This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to its short form base shelf prospectus dated September 17, 2025, as amended on December 19, 2025.

NEW YORK & TORONTO – November 16, 2026 – Helus Pharma Inc.

Prompts

Helus Pharma Inc. (ticker HELP), listed in United States.

Company History

Date Change Detail
Oct 1, 2026 Renamed CYBIN INC. → Helus Pharma Inc.
— Former tickers CYBN

ETFs Holding Helus Pharma Inc.

ETF Weight in ETF Shares Market value As of
PSIL 7.41% 392,147 $ 2.823M Nov 17, 2026